

# Urinary leukotriene E4 at 12 months and influencing factors

Stencel-Gabriel K ( 1 ), Czuba Z ( 2 ), Gabriel I ( 3 ), Majda A ( 1 )

1. Department of Pediatrics, Bytom, Medical University of Silesia
2. Department of Microbiology and Immunology, Zabrze, Medical University of Silesia
3. Department of Gynecology, Obstetrics and Oncological Gynecology, Bytom, Medical University of Silesia

Corresponding author:  
Krystyna Stencel-Gabriel  
ul. Batorego 15  
41-902 Bytom

**Keywords:** leukotriene E4, infants, allergy, urine.

## Summary

### Objective

LTE<sub>4</sub> is the end point of cysLTs pathway and its only stable product. Its role was discussed in asthma and AEDS.

We aimed to investigate the impact of genetic and environmental factors ( sex, maternal positive family atopy history, breastfeeding, passive smoking and pet exposure ).

60 newborns ( including 30 boys ) were enrolled in the study. Each child was examined at 12 months and urine samples for urinary LTE<sub>4</sub> measurement were collected. All samples were processed using ACE<sup>TM</sup> Enzyme Immunoassay Kit ( Cayman Chemical, Ann Arbor, MI, USA ).

The mean level of urinary LTE<sub>4</sub> at 12 months was 186,99 pg/ml ( median: 159,0; CI 95%: 157,79- 221,59 ). The Shapiro- Wilk test showed that the distribution of the levels of urinary LTE<sub>4</sub> were abnormal. 12- month- old girls had higher urinary LTE<sub>4</sub> levels than boys ( mean: 270,50 vs. 193,55 ), but maternal positive atopy history, pet exposure, tobacco smoking or length of breastfeeding had no impact on urinary LTE<sub>4</sub> excretion.

### Conclusions

In conclusion, most of genetic or environmental factors do not change levels of urinary LTE<sub>4</sub> in infants.

CysLTs are potent mediators of airway narrowing, edema, smooth muscle proliferation, and increased mucus production during asthmatic attack. LTE<sub>4</sub> is a potent bronchoconstrictor in human [ 3 ] and asthmatic airways might be selectively hyperresponsive to LTE<sub>4</sub> in contrast to other cysLTs [ 11 ].

CysLTs also are involved in the inflammation of the skin in AEDS, possibly through chemotaxis of inflammatory cells, vasodilatation and oedema [ 16 ]. Urinary LTE<sub>4</sub> is significantly elevated in children with AD [ 5 ]. It was also shown that urinary LTE<sub>4</sub> concentration was correlated with SCORAD.

LTE<sub>4</sub> is an effect of leukotriene C<sub>4</sub> conversion through sequential enzymatic removal of glutamic acid and then glycine. So far, LTE<sub>4</sub> has received little attention because it binds poorly to the classical type 1 and 2 cysLT receptors and is much less active on normal airways than LTC<sub>4</sub> or LTD<sub>4</sub>. Recent studies have begun to uncover receptors selective for LTE<sub>4</sub>: PRY<sub>12</sub>, an adenosine diphosphate receptor, and CysLT<sub>E</sub>R.

The past three decades have been characterized by an increase in the prevalence of allergic diseases, particularly in childhood [ 18 ]. While the increase of asthma in developed countries seems to stabilise, at the same time we observe the rapid increase in atopic eczema prevalence [ 1 ]. The burst of allergies in the western countries, including Poland, is suggested to be provoked to due to both genetic and environmental factors including sex, positive maternal and family atopy history, cigarette smoking, pets, social and economic status.

As far as we known, there are no previous studies aiming to investigate the correlation between the levels of urinary LTE<sub>4</sub> and sex, cigarette smoking, breastfeeding, pets and positive maternal history of allergy among the Polish infants. Therefore, the aim of our study was to demonstrate the influence of selected factors ( sex, cigarette smoking, breastfeeding,

pets and positive maternal history of allergy ) on the levels of urinary LTE<sub>4</sub> in 12- months-old children.

## **Methods**

### **Subjects**

60 newborns born vaginally at term were enrolled in the study after the parental informed consent was obtained. The exclusion criteria were: newborns born from multiple pregnancies or complicated pregnancies ( maternal chronic disease, PIH, GDM, GBS ), newborns with congenital defects or intrauterine infection.

At the time of delivery all parents completed a standardized questionnaire, including information on pregnancy, birth, sex, birth weight, social, economical and maternal factors, family atopy history, passive smoking. These children have been followed at the age of 3, 6, 12 months. At every follow- up, detailed questionnaires were completed with the parents for each child regarding breastfeeding, passive smoking, infections and allergic symptoms.

Family allergy score ( FAS ) system was used for assessment of family allergy history [ 10 ].

The study was approved by the local research ethics committee.

### **Collection and storage of samples**

At the age of 12 months, each child was examined by the same physician to exclude infection or present allergic symptoms before the urine was obtained in the laboratory. The samples were immediately centrifuged to remove cellular debris at 10,00x g for 10 min, the supernatant was then removed, coded and stored in aliquots of 5 ml at – 70°C until analysis.

### **LTE<sub>4</sub> measurement**

LTE<sub>4</sub> in urine was measured using ACE<sup>TM</sup> Enzyme Immunoassay Kit ( Cayman Chemical, Ann Arbor, MI, USA ). All measurements were done in duplicate and the mean value was calculated. This assay is based on the competition between LTE<sub>4</sub> and an LTE<sub>4</sub>-acetylcholinesterase conjugate ( LTE<sub>4</sub> tracer ) for a limited amount of LTE<sub>4</sub> antiserum. Because the concentration of LTE<sub>4</sub> tracer is held constant while the concentration of LTE<sub>4</sub> varies, the amount of LTE<sub>4</sub> tracer that is able to bind to the LTE<sub>4</sub> antiserum will be inversely proportional to the concentration of LTE<sub>4</sub> in the well. The U- LTE<sub>4</sub> concentration is expressed as picograms per milligram and the detection limit in the assay was < 8 pg/ml.

#### Statistical analysis

Data were analyzed using MedCalc 9.6 ( MedCalc, Mariakerke, Belgium ). Data were expressed as mean  $\pm$  SD. Urinary LTE<sub>4</sub> concentration was log-transformed ( log-LTE<sub>4</sub> ) before analysis because its distribution was not normal. Logistic regression analysis was used to assess the influence of analyzed factors on urinary LTE<sub>4</sub> at 12 months. P< 0,05 was considered to be statistically significant.

### **Results**


Sixty newborns ( 30 boys ) were recruited with a mean level of urinary LTE<sub>4</sub> at 12 months of 186,99 pg/ml ( median: 159,0; CI 95%: 157,79- 221,59 ). The Shapiro- Wilk test showed that the distribution of the levels of urinary LTE<sub>4</sub> were abnormal.

Table I presents the mean levels of urinary LTE<sub>4</sub> detected depending on sex, positive maternal atopy history, passive smoking, breastfeeding and pets.

The levels of urinary LTE<sub>4</sub> differ between boys ( 1 ) and girls ( 2 ) at the of 12 months ( p<0,05 ).(Table I), ( Fig. 1 ).

**Table I. The mean levels of urinary LTE<sub>4</sub> depending on genetic and environmental factors (sex, positive maternal atopy history, passive smoking, breastfeeding and pets ); pg/ml.**

	Number	Mean level of urinary LTE <sub>4</sub>	p
<b>Sex</b>	<b>60</b>	<b>186,99</b>	<b>0,03</b>
Boys	30	193,55	
Girls	30	270,50	
Maternal atopy history	60	186,99	0,39
Yes	18	208,94	
No	42	178,30	
Passive smoking	60	186,99	0,19
Yes	23	196,51	
No	38	254,22	
Breastfeeding*	60	186,99	0,12
Yes	23	168,85	
No	37	220,76	
Pets	60	186,99	0,76
Yes	13	196,21	
No	47	184,51	



**Fig. 1. Levels of urinary LTE<sub>4</sub> at 12-months old infants ( 1 boys, 2 girls ); p<0,05; pg/ml.**

## Discussion

In this study, we demonstrated that levels of urinary LTE<sub>4</sub> were higher in 12-months old girls than boys. We did not observe any difference in urinary LTE<sub>4</sub> levels depending on cigarette smoking, the length of breastfeeding or presence of pet at home.

It is surprising that exposure to cigarette smoking have not influenced urinary LTE<sub>4</sub> excretion. Previous reports showed that, beside of RSV, secondhand cigarette smoking increases urinary LTE<sub>4</sub> both in healthy infants and infants with RSV- bronchiolitis [ 8 ]. The study by Kott et al. noted the increase of urinary LTE<sub>4</sub> only in children exposed to cigarette smoke without parental positive history of asthma. Additionally, their observation is limited to high exposure to cigarette smoke. This may explain the difference in our study. Firstly, we had not divided the exposed group of infants into further subgroups according to the amount of cigarettes smoked a day by parents. Secondly, we had not divided children according to both passive smoking and parental atopy family history. Our assumption that only high exposure of tobacco smoke can produce subsequent elevation of urinary LTE<sub>4</sub> in infants might be sustained by earlier studies [ 4, 13 ]. Piedimonte et al. observed higher levels of urinary LTE<sub>4</sub> in children with bronchiolitis and with an atopic/asthmatic family background which is inconsistent with our observation that family atopy history did not influence leukotriene synthesis. In our opinion, bronchiolitis itself was triggering mast cells and eosinophils to produce leukotriens. Atopic background was only additional minor factor that came into importance only because of airways irritation with RSV.

Although beneficial effect of breastfeeding was widely reported [ 6,17 ], we have not observed any effect of breastfeeding longer than 3 months on urinary LTE<sub>4</sub> levels at 12-months old children. It is hard to debate whether our results are acceptable because there are no previous studies that might be compared to our results. Similarly, pet exposure have no impact on urinary LTE<sub>4</sub> excretion at 12 months. Recent study reported exposure to cat

allergens early in life increased the risk of late childhood asthma and bronchial hyperresponsiveness, but not the risk of allergic sensitization [ 2 ]. They did not observe, however, any impact of early exposure to dog allergens. As we mentioned above, this might be due to lack of subgroup selection eg. infants exposed to cat or dog or guinea pig. It seems that this problem should be further investigated in larger population study because previous studies have shown that the urinary LTE<sub>4</sub> concentration is useful in demonstrating cysLTs release in vivo during allergen challenge [ 9,15 ]. Additionally, LTE<sub>4</sub> is a potent bronchoconstrictor in human [ 3 ] and it was shown that asthmatic airways might be selectively hyperresponsive to LTE<sub>4</sub> in contrast to other cysLTs [ 11 ]. It might be reasonable to enlarge the studied group with selection of infants with wheezing or recurrent bronchitis and to investigate pet exposure in this selected group.

We demonstrated a significant dependence of urinary LTE<sub>4</sub> on sex. Girls had higher mean levels of urinary LTE<sub>4</sub> than boys. The trend to higher levels of urinary LTE<sub>4</sub> in girls was previously observed by Rabinovitch et al [ 14 ]. On the other hand, other studies performed at the older age group had showed no association between sex and urinary LTE<sub>4</sub> [ 7,12 ].

The ability to predict the risk for having allergic disease in later childhood is enormously helpful in terms of offering an accurate prognosis to parents and identifying children for investigation of prevention strategies. Thus, it was proven that urinary LTE<sub>4</sub> is helpful as pediatric biomarker in asthma or atopic eczema. It seems it is especially important in selecting high- risk infant girls but further studied should be performed.

What is already known on this topic is a little information about levels of urinary LTE<sub>4</sub> in children, especially in infants. Additionally, it should be mentioned that most of the previous studies reported levels of urinary LTE<sub>4</sub> in children with asthma exacerbation or AEDS.

What this study adds is that levels of urinary LTE<sub>4</sub> are different between boys and girls in Polish population. It is noteworthy, that these children were followed for the first year of their life and were not recruited as sick children.

## References

1. Asher MI, Montefort S, Bjorksten B et al. 2006. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood. ISAAC Phases One and Three repeat multicountry cross-sectional surveys. *Lancet* 368: 733- 743.
2. Bertelsen RJ, Lodrup Carlsen KC, Carlsen KH et al. 2010. Childhood asthma and early life exposure to indoor allergens, endotoxin and beta(1,3)- glucans. *Clin Exp Allergy* 40: 307- 16.
3. Davidson AB, Lee TH, Scanlon PD et al. 1987. Bronchoconstrictor effects of leukotriene E<sub>4</sub> in normal and asthmatic subjects. *Am Rev Respir Dis* 135: 333-7.
4. Fauler J, Frolich JC. 1997. Cigarette smoking stimulates cysteinyl leukotriene production in man. *Eur J Clin Invest* 27: 43-7.
5. Hon KLE, Leung TF, Ma KC et al. 2004. Urinary leukotriene E<sub>4</sub> correlates with severity of atopic dermatitis in children. *Clin Exp Dermatol* 29: 277- 281.
6. James DC, Lessen R. 2009. American Dietetic Association. Position of American Dietetic Association: promoting and supporting breastfeeding. *J Am Diet Assoc* 1926- 42.
7. Kaminsky DA, Jones K, Schoene RB, Voelkel NF. 1996. Urinary leukotriene E<sub>4</sub> levels in high-altitude pulmonary edema. A possible role of inflammation. *Chest* 110: 939- 45.

8. Kott KS, Salt BH, McDonald RJ et al. 2008. Effect of secondhand cigarette smoke, RSV bronchiolitis and parental asthma on urinary cysteinyl LTE<sub>4</sub>. *Pediatr Pulmonol* 43: 760-6.
9. Kumlin M, Dahlen B, Bjorck T et al. 1992. Urinary excretion of leukotriene E<sub>4</sub> and 11- dehydro- thromboxane B<sub>2</sub> in response to bronchial provocations with allergen, aspirin, leukotriene D<sub>4</sub>, and histamine in asthmatics. *Am Rev Respir Dis* 146: 96- 103.
10. Liao SY, Liao TN, Chiang BL et al. 1996. Decreased production of IFN gamma and increased production of IL-6 by cord blood mononuclear cells of newborns with a high risk of allergy. *Clin Exp Allergy* 26: 397-405.
11. O' Hickey SP, Arm JP, Rees PJ et al. 1998. The relative responsiveness to inhaled leukotriene E<sub>4</sub>, methacholine and histamine in normal and asthmatic subjects. *Eur Respir J* 1: 913-7.
12. Oosaki R, Mizushima Y, Mita H et al. 1997. Urinary leukotriene E<sub>4</sub> and 11- dehydrothromboxane B<sub>2</sub> in patients with aspirin- sensitive asthma. *Allergy* 52: 470-3.
13. Piedimonte G, Renzetti G, Auais A et al. 2005. Leukotriene synthesis during respiratory syncytial virus bronchiolitis: influence of age and atopy. *Pediatr Pulmonol* 40: 285- 91.
14. Rabinovitch N, Strand M, Stuhlman K, Gelfand EW. 2008. Exposure to tobacco smoke increases leukotriene E<sub>4</sub>- related albuterol usage and response to montelukast. *J Allergy Clin Immunol* 121: 1365- 71.
15. Sladek K, Dworski R, Fitzgerald GA et al. 1990. Allergen- stimulated release of thromboxane A<sub>2</sub> nad leukotriene E<sub>4</sub> in humans. Effect of indomethacin. *Am Rev Respir Dis* 141: 1441- 5.
16. Wedi B, Kapp A. 2001. Pathophysiological role of leukotriens in dermatological diseases. *BioDrugs* 15: 729-743.

17. Verhasselt V. 2010. Neonatal tolerance under breastfeeding influence: the presence of allergen and transforming growth factor- beta in breast milk protects the progeny from allergic asthma. *J Pediatr* 156: S16-20.
18. von Hertzen L, Haathela T. 2005. Signs of reversing trends in prevalence of asthma. *Allergy* 60: 283- 292.